135 related articles for article (PubMed ID: 28042794)
1. Effect of onabotulinum toxin type a intraprostatic injection on the outcome of Benign Prostatic Hyperplasia patients refractory to medical therapy: A 2-year follow-up study.
Rodrigues de Carvalho TG; Pinto R; Cruz F; Silva J
Arch Esp Urol; 2016 Dec; 69(10):719-726. PubMed ID: 28042794
[TBL] [Abstract][Full Text] [Related]
2. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia.
de Kort LM; Kok ET; Jonges TN; Rosier PF; Bosch JL
Urology; 2012 Oct; 80(4):889-93. PubMed ID: 22854138
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
[TBL] [Abstract][Full Text] [Related]
4. Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption.
Silva J; Silva C; Saraiva L; Silva A; Pinto R; Dinis P; Cruz F
Eur Urol; 2008 Jan; 53(1):153-9. PubMed ID: 17825981
[TBL] [Abstract][Full Text] [Related]
5. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia.
Chuang YC; Chiang PH; Yoshimura N; De Miguel F; Chancellor MB
BJU Int; 2006 Nov; 98(5):1033-7; discussion 1337. PubMed ID: 16956361
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy.
Kuo HC; Liu HT
Scand J Urol Nephrol; 2009; 43(3):206-11. PubMed ID: 19308807
[TBL] [Abstract][Full Text] [Related]
7. Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: Initial experience with Dysport.
Nikoobakht M; Daneshpajooh A; Ahmadi H; Namdari F; Rezaeidanesh M; Amini S; Pourmand G
Scand J Urol Nephrol; 2010 Apr; 44(3):151-7. PubMed ID: 20201752
[TBL] [Abstract][Full Text] [Related]
8. Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment.
Silva J; Pinto R; Carvalho T; Botelho F; Silva P; Oliveira R; Silva C; Cruz F; Dinis P
BMC Urol; 2009 Aug; 9():9. PubMed ID: 19682392
[TBL] [Abstract][Full Text] [Related]
9. Prostate botulinum A toxin injection--an alternative treatment for benign prostatic obstruction in poor surgical candidates.
Kuo HC
Urology; 2005 Apr; 65(4):670-4. PubMed ID: 15833506
[TBL] [Abstract][Full Text] [Related]
10. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial.
Crawford ED; Hirst K; Kusek JW; Donnell RF; Kaplan SA; McVary KT; Mynderse LA; Roehrborn CG; Smith CP; Bruskewitz R
J Urol; 2011 Sep; 186(3):965-70. PubMed ID: 21791356
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Benign Prostatic Hyperplasia by Ultrasound-Guided Botulinum Toxin Type A Injection.
Ding XD; Chen HX; Xiao HQ; Wang W; Ding ZG; Zhang GB; Fu DG
Cell Biochem Biophys; 2015 Nov; 73(2):357-359. PubMed ID: 27352323
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia.
Chughtai B; Dunphy C; Lee R; Lee D; Sheth S; Marks L; Kaplan SA; Te AE
Can J Urol; 2014 Apr; 21(2):7217-21. PubMed ID: 24775575
[TBL] [Abstract][Full Text] [Related]
13. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study.
Maria G; Brisinda G; Civello IM; Bentivoglio AR; Sganga G; Albanese A
Urology; 2003 Aug; 62(2):259-64; discussion 264-5. PubMed ID: 12893330
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia.
McVary KT; Roehrborn CG; Chartier-Kastler E; Efros M; Bugarin D; Chen R; Patel A; Haag-Molkenteller C
J Urol; 2014 Jul; 192(1):150-6. PubMed ID: 24508634
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin A injection to the bladder neck and urethra for medically refractory lower urinary tract symptoms in men without prostatic obstruction.
Chen JL; Chen CY; Kuo HC
J Formos Med Assoc; 2009 Dec; 108(12):950-6. PubMed ID: 20040460
[TBL] [Abstract][Full Text] [Related]
16. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results.
Brisinda G; Cadeddu F; Vanella S; Mazzeo P; Marniga G; Maria G
Urology; 2009 Jan; 73(1):90-4. PubMed ID: 18995889
[TBL] [Abstract][Full Text] [Related]
17. Intraprostatic injections for lower urinary tract symptoms/benign prostatic enlargement treatment.
Lombardo R; Andersson KE; Tubaro A; De Nunzio C
Minerva Urol Nefrol; 2018 Dec; 70(6):570-578. PubMed ID: 30298711
[TBL] [Abstract][Full Text] [Related]
18. Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function.
Silva J; Pinto R; Carvalho T; Botelho F; Silva P; Silva C; Cruz F; Dinis P
BJU Int; 2011 Jun; 107(12):1950-4. PubMed ID: 21105985
[TBL] [Abstract][Full Text] [Related]
19. Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates.
Hamidi Madani A; Enshaei A; Heidarzadeh A; Mokhtari G; Farzan A; Mohiti Asli M; Esmaeili S
World J Urol; 2013 Feb; 31(1):235-9. PubMed ID: 22411419
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trial of belladonna and opiate suppository during intravesical onabotulinum toxin A injection.
LeClaire EL; Duong J; Wykes RM; Miller KE; Winterton TL; Bimali M
Am J Obstet Gynecol; 2018 Nov; 219(5):488.e1-488.e7. PubMed ID: 29902447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
